05272nam 2201585z- 450 991036774390332120231214133452.03-03921-655-4(CKB)4100000010106278(oapen)https://directory.doabooks.org/handle/20.500.12854/56155(EXLCZ)99410000001010627820202102d2019 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierPheochromocytoma (PHEO) and Paraganglioma (PGL)MDPI - Multidisciplinary Digital Publishing Institute20191 electronic resource (380 p.)3-03921-654-6 This book outlines some new advances in genetics, clinical evaluation, localization, therapy (newly including immunotherapy) of pheochromocytoma and paraganglioma including their metastatic counterparts. Well-known and experienced clinicians and scientists contributed to this book to include some novel approaches to these tumors. This book will serve to various health care professionals from different subspecialties, but mainly oncologists, endocrinologists, endocrine surgeons, pediatricians, and radiologists. This book shows that the field of pheochromocytoma/paraganglioma is evolving and a significant progress has been made in last 5 years requiring that health care professionals and scientists will learns new information and implement it in their clinical practice or scientific work, respectively. This book should not be missed by anybody who is focusing on neuroendocrine tumors, their newest evaluation and treatment.Pheochromocytoma polycythemiapeptide receptor radiotherapyvasculogenesiscatecholaminesneuroendocrineGTVadaptive immunitytherapy resistancehistologytransgenic micecryoablationspheroidsenergy metabolismsomatostatinomaangiogenesispheochromocytomaSDHDpercutaneous ethanol injectionmetanephrinesSDHBglobal longitudinal strainmutationnormetanephrinescatecholaminePASSPGL177Lu-DOTATATEchromosomal alterationspeckle-tracking echocardiographylL-6dogpercutaneous ablationstem-like tumor cellsEPAS1neural crestfluorescence imagingneutrophilxenograftinflammationhead and neckweighted standard deviationFGF21calorimetryHIFaverage real variabilitynext-generation sequencingadrenocortical carcinomacarotid bodyhypoxia-inducible factorparagangliomasuccinate dehydrogenaseblood pressure variabilityarrhythmiamortalityNF1toll-like receptorGAPPNETsubclinical systolic dysfunctionpheochromocytoma and paragangliomaPET-CTpan-cancer analysismouse pheochromocytoma cellsinnate immunityneurogenesisneuroendocrine tumorobesityhypotensionhypoxiaCNV detection18F-FDOPAcomparative genomicsadrenomedullary functionPCCpathogen-associated molecular patternsadrenal tumorradiotherapy11C-hydroxy-ephedrineradiofrequency ablationPPGLminimally invasive proceduresporadicdiabetes mellitusadrenal incidentalomagermline mutationimmunotherapyVHLimmunohistochemistrymetastatic OR malignant pheochromocytomaerythropoietinpostoperativetargeted therapyPRRTmetastaticmitochondriaT cellTCA cyclemeta-analysispseudohypoxiaectopic secretionradiosensitizationchromogranin AhereditaryhypertensionPETphosphorylation tyrosine hydroxylasePacak Karelauth881323Taïeb DavidauthBOOK9910367743903321Pheochromocytoma (PHEO) and Paraganglioma (PGL)3030537UNINA